Controlled document PF-015A
PLEXUS LUMBOSACRALIS Phase 1 Master Formula
Record identification
- Document ID
- PF-015A
- Document type
- Template
- Status
- Documented
- Source
- Standardisation & Production of SIRIAM Products
Overview
PF-015A
PRODUCT FORMULA CARD
SIRIAM PLEXUS LUMBOSACRALIS DUO – PHASE 1 (NERVE RELEASE)
DOCUMENT CONTROL
Field
Product ID
Formula ID
Document
Product
Anatomical Region
Therapeutic Phase
Product Type
Standard Batch
Version
Status
Internal QR
| Value |
|---|
| SIR-PLS-001 |
| MF-015 |
| PF-015A |
| PLEXUS LUMBOSACRALIS DUO – Phase 1 |
| L4–S2 |
| Nerve Release |
| Topical Magistral Cream |
| 100 g |
| 2.0 |
| 🔒 LOCKED |
| ☐ |
1. PRODUCT PURPOSE
Field
Clinical Objective
Anatomical Region
Primary Biological Target
Therapeutic Phase
Product Type
The magistral fiche describes Phase 1 as a release phase focused on neurodermal, myofascial and neurovegetative modulation.
| Description |
|---|
| Neurodermal modulation of the lumbosacral plexus |
| L4–S2 |
| Myofascial release, peripheral afferent unloading and autonomic modulation |
| Phase 1 – Release |
| Topical Magistral Cream |
2. MASTER FORMULA
Ingredient quantities are taken directly from the uploaded Phase 1 magistral fiche, with the agreed SQMS standardisation for Vitamin E and Silicea.
| Code |
|---|
| Official Ingredient |
| Supplier |
| Master Qty |
| Unit |
| Phase |
| PC-001 |
| Lanette Cream FNA |
| 65.00 |
| g |
| B |
| PC-002 |
| Aqua Purificata |
| 18.00 |
| g |
| W |
| SC-001 |
| Magnesium Chloride |
| 3.00 |
| g |
| W |
| SC-002 |
| MSM |
| 3.00 |
| g |
| W |
| AC-003 |
| Palmitoylethanolamide (PEA) |
| 2.00 |
| g |
| D |
| BE-001 |
| Boswellia serrata |
| 1.00 |
| g |
| D |
| BE-010 |
| Hypericum perforatum D6 |
| 0.50 |
| mL |
| C |
| BE-009 |
| Ruta graveolens |
| 0.40 |
| mL |
| C |
| BE-008 |
| Arnica montana D6 |
| 0.70 |
| mL |
| C |
| BE-002 |
| Copaiba Oil |
| 0.70 |
| mL |
| C |
| AC-008 |
| Magnesium Bisglycinate |
| 1.00 |
| g |
| W |
| OC-003 |
| Squalane |
| 2.00 |
| g |
| L |
| AC-002 |
| Betaine (TMG) |
| 0.80 |
| g |
| W |
| SC-003 |
| D-Panthenol |
| 0.80 |
| g |
| W |
| SC-004 |
| Vitamin E Full Spectrum |
| 0.50 |
| g |
| L |
| SC-005 |
| Silicea Gel (+1 drop Silicea D8) |
| 2.00 |
| g |
| C |
| PR-001 |
| Cosgard 221 |
| 0.70 |
| g |
| C |
3. MANUFACTURING WORKFLOW
Standard SQMS Lanette Manufacturing Workflow
Step
1
2
3
4
5
6
7
8
9
10
11
The preparation sequence follows the Lanette protocol described in the source fiche.
| Action |
|---|
| ✓ |
| Verify raw materials |
| □ |
| Prepare water phase |
| □ |
| Prepare dispersion phase |
| □ |
| Pre-disperse PEA & Boswellia |
| □ |
| Emulsification |
| □ |
| Cool below 40°C |
| □ |
| Add thermolabile ingredients |
| □ |
| Add Silicea Gel (+1 drop Silicea D8) |
| □ |
| Quality Control |
| □ |
| Fill airless dispensers |
| □ |
| Batch Release |
| □ |
4. QUALITY CONTROL
Standard SQMS Quality Control
5. BATCH RELEASE
Standard SQMS Batch Release
6. CLINICAL APPLICATION
Field
Anatomical Region
Primary Zone
Secondary Zone
Additional Zone
Posterior Zone
Additional Posterior Zones
Frequency
Treatment Phase
Clinical application zones and EMG objectives are based on the magistral protocol.
| Value |
|---|
| L4–S2 |
| Trochanteric region |
| Lateral hip |
| Tensor fasciae latae projection |
| L4–S2 paravertebral |
| Gluteal region, piriformis, SI region, proximal ITB |
| 1–2× daily |
| Weeks 1–2 |
Related documents
Platform modules